Core Viewpoint - The approval of Chloride Dihydropyridine Injection by the National Medical Products Administration of China represents a significant advancement for the company in the cardiovascular treatment sector, addressing an unmet clinical need for emergency hypertension medications [1] Company Summary - The product is a dihydropyridine calcium channel blocker, classified as a rapid-acting intravenous antihypertensive drug, suitable for patients who cannot take oral medications or have poor expected responses to oral treatments [1] - The injection comes in two formulations: 50ml with 25mg and 100ml with 50mg [1] - The approval enhances the company's product pipeline in the cardiovascular disease treatment area, increasing its competitiveness in this field [1] Product Advantages - The product offers significant advantages over commonly used clinical medications, including faster onset of action, allowing for rapid, real-time, and precise blood pressure control [1] - It is particularly suitable for patients with liver and kidney dysfunction, as dosage adjustments are not required during treatment [1] - The product does not require dilution or preparation, which can significantly benefit patients at risk of fluid overload [1] Market Implications - The approval is expected to fill a clinical demand gap for emergency hypertension medications, thereby potentially increasing market share and revenue for the company in the cardiovascular sector [1]

Core Viewpoint - The approval of Chloride Dihydropyridine Injection by the National Medical Products Administration of China represents a significant advancement for the company in the treatment of hypertension, particularly for patients who cannot take oral medications [1] Group 1: Product Details - The product is a dihydropyridine calcium channel blocker, classified as a rapid-acting intravenous antihypertensive drug [1] - It is specifically designed for patients who are unsuitable for oral medication or have poor expected outcomes from oral treatments [1] Group 2: Advantages - The injection has notable advantages over commonly used clinical medications, including faster onset of action and the ability to achieve rapid, real-time, and precise blood pressure control [1] - It is particularly suitable for patients with liver and kidney dysfunction, as dosage adjustments are not required during treatment [1] - The product does not require dilution or preparation, which significantly benefits patients at risk of fluid overload [1] Group 3: Market Impact - The approval will enhance the company's product pipeline in the cardiovascular disease treatment sector, increasing its competitiveness in this field [1] - It is expected to address the clinical demand gap for emergency hypertension medications [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 氯維地平乳狀注射液獲藥品註冊批件 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 佈，本集團開發的氯維地平乳狀注射液(50ml: 25 mg、100ml: 50mg)（「該產品」）已獲得中華人 民共和國國家藥品監督管理局頒發的藥品註冊批件。 該產品是二氫吡啶類鈣通道阻滯拮抗劑，屬於速效靜脈降壓藥，適用於治療不適宜口服或 預期口服藥物治療效果不佳的高血壓患者。與臨床常用的治療藥物相比，該產品具有以下 顯 著 優 勢 ： 起 效 更 快 ， 可 實 現 血 壓 的 快 速 、 實 時 、 精 準 調 控 ； 更 適 用 於 肝 腎 功 能 異 常 患 者 ， 其 用 藥 期 間 無 需 調 整 劑 量 ； 使 用 時 無 需 稀 釋 配 製 ...

Core Viewpoint - YKYY029 injection, developed by YKANG Pharmaceutical and Hangzhou Tianlong, has received approval for clinical trials, marking a significant milestone in the company's drug development efforts [1][2]. Group 1: Drug Development - YKYY029 is a novel siRNA drug targeting the AGT gene, featuring a unique sequence and a proprietary delivery system developed by the company, which has been granted a national patent [2]. - The drug utilizes a GalNAc delivery system for efficient liver-targeted delivery, enhancing its therapeutic potential [2]. - The approval of the IND for YKYY029 is seen as a testament to the company's capabilities in new drug development, reinforcing its competitive edge in the cardiovascular disease sector [3]. Group 2: Preclinical Research - Preclinical studies have demonstrated significant AGT suppression activity in both in vitro and in vivo models [3]. - In pharmacological trials on spontaneously hypertensive crabs, YKYY029 maintained normal blood pressure levels, achieving a reduction of over 20 mmHg in systolic blood pressure at the study endpoint [3]. - Toxicity tests in SD rats and crabs showed no adverse reactions at high doses, indicating good safety and tolerability [3]. Group 3: Publication and Future Potential - Research papers related to YKYY029 have been published in the reputable journal "Molecular Therapy Nucleic Acids," highlighting the drug's enhanced efficacy and safety in various animal models [3]. - The combination of optimized sequence composition, modification patterns, and delivery systems is expected to further improve the drug's clinical trial outcomes for hypertension treatment [3].